Skip to main content


Table 3 Incidence of treatment emergent adverse events

From: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

TEAE CategoryN = 495
Any TEAE371 (74.9)
Any treatment-relateda TEAE223 (45.1)
Any serious TEAE34 (6.9)
Any treatment-relateda serious TEAE7 (1.4)
Any TEAE leading to discontinuation84 (17.0)
Any treatment-relateda TEAE leading to discontinuation66 (13.3)
Any serious TEAE leading to discontinuation8 (1.6)
Any TEAE leading to death1 (0.2)
Treatment-related TEAEs (≥2% patients)
 Dyskinesia57 (11.5)
 Dry mouth32 (6.5)
 Dizziness24 (4.8)
 Nausea22 (4.4)
 Constipation20 (4.0)
 Insomnia12 (2.4)
 Hallucination11 (2.2)
 Fall10 (2.0)
TEAEs leading to discontinuation (≥1% patients)
 Nausea10 (2.0)
 Constipation7 (1.4)
 Hallucination6 (1.2)
 Dizziness5 (1.0)
 Dyskinesia5 (1.0)
  1. aTreatment-related TEAEs were any TEAEs that were considered at least possibly related by the investigator and include the events with missing relationship assessment